Hi Dougal, I personally would be shattered if this co went for 40c. But thats every investors seperate call on price target.
I dont believe POHs cost would be $700k a month now. Pretty much everything is covered by partners cost wise.
Except the Oxy development. Even the oxy can be delayed further if the revenue doesnt match. So that is not really an overhead either. 3M patches excepted.
Are you talking specifically about Elixia personal care? Or are you talking about Cellucreme? Or both?
I assume you refer to both.
Poh is a multiheaded beast and even if Elixia fails there are plenty more projects happening. Yes it may mean another cap raising or a sale of some area of poh to keep the oxy trials moving. But it would be a blip in my vision as there are just so many market segments to be exploited with TPM.
At some point a business has to execute its plan and it is considered a risk. But there are plenty of successes for having a crack.
Poh is not hiding in a test tube. It is out there signing deals with big names and big varied markets and on a pretty regular basis.
A few years ago I looked at the pipeline and there were 5 main projects. On a 1 in 5 success basis I expect 1 to succeed at least. But the science is yet to let us down.(Dont want to temp fate) So far, Nestle excepted, there has been no bad news other than raising money at cheap prices, unfortunately.
But the pipeline is about 3 times bigger now with most of that covered by someone else.
She'll be right mate.
- Forums
- ASX - By Stock
- the positive side if elixia launch ?fails?
AVE
avecho biotechnology limited
Add to My Watchlist
12.5%
!
0.4¢

Hi Dougal, I personally would be shattered if this co went for...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
-0.001(12.5%) |
Mkt cap ! $11.10M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $453 | 129.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
40 | 33486086 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 8328117 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
39 | 32986086 | 0.003 |
15 | 16879866 | 0.002 |
15 | 57221222 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 8218985 | 6 |
0.005 | 13262502 | 18 |
0.006 | 31623747 | 5 |
0.007 | 4498187 | 12 |
0.008 | 4722624 | 6 |
Last trade - 13.52pm 04/07/2025 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online